<DOC>
	<DOCNO>NCT00777985</DOCNO>
	<brief_summary>The study compare effect bosentan , endothelin receptor antagonist , nasal continuous positive airway pressure ( nCPAP ) , obstructive sleep apnea current reference treatment , diastolic blood pressure untreated mildly hypertensive sleep apnea patient . The hypothesis block endothelin receptor drug systemic blood pressure lower effect nCPAP sleep apnea patient .</brief_summary>
	<brief_title>Preventive Effects Bosentan Systemic Cardiovascular Consequence Sleep Apnea</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Documented obstructive sleep apnea untreated mild systemic hypertension pregnancy lactation daytime alveolar hypoventilation severe arterial hypertension ( systolic pressure &gt; 180 mmHg ; diastolic pressure &gt; 110 mmHg ) treatment antihypertensive drug cardiovascular disorder mild hypertension severe daytime sleepiness ( score EPWORTH sleepiness scale â‰¥15 ) atrisk occupation contraindication nCPAP treatment know allergy bosentan active treatment drug whose efficacy reduce cytochrome P450 , 2C9 , 3A4 and2C19 isoenzyme activation active treatment drug act systemic arterial blood pressure endothelial function liver kidney dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Cardiovascular system</keyword>
	<keyword>Sleep</keyword>
	<keyword>Endothelial function</keyword>
	<keyword>Endothelin system</keyword>
</DOC>